Arkolith/Insider Trading/KALV/Form 4

Yea Christopher

CHIEF DEVELOPMENT OFFICERKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed May 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$63K
Net Open-Market Flow
-$63K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 22, 2026Sell(S)2K$26.78$63K229K
May 21, 2026Option exercise(M)4K——231K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 21, 2026Option exercise(M)4K—$041K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001691102-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for KalVista Pharmaceuticals, Inc.

Build

Ask your agent about KALV insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001691102-26-000005"
Ask your agent
Use Arkolith to summarize insider buying and selling at KalVista Pharmaceuticals, Inc.
over the last 90 days and cite the filings.